Board meeting on Oct 26, 2026 to consider Q2 and H1 FY27 results

Profit growth above 25%EBITDA margin expansionResults View source PDF Explain this filing

MANKIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.4%Reaction day

₹2380.00

prior close

₹2380.00

announcement price

After-mkt

timing

Nifty Midcap 150market+1.4%-1.8% vs market

Pharmaceuticals peers, median of 168sector-0.2%-0.2% vs sector

On the reaction day the stock moved 1.8 pts less than Nifty Midcap 150 and 0.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.7

10m

-1.0

15m

-0.4

30m

-1.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.4+1.4-1.8-0.2-0.2

Next day

+0.8+1.4-0.6-0.3+1.1

-0.4+2.4-2.9-0.4-0.1

-1.9+2.4-4.3-0.7-1.2

-1.4+2.1-3.4-1.1-0.2

-4.4+2.0-6.4-0.8-3.6

-4.0-0.5-3.4-4.2+0.2

15d

+4.3-0.0+4.3-2.8+7.0

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 168Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Mankind Pharma has informed BSE that its Board of Directors will meet on Monday, October 26, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The trading window for dealing in the company shares remains closed till October 28, 2026, in line with insider trading rules.

Likely market impact

Routine pre-results intimation. Investors should await the actual Q2 and H1 FY27 numbers for any stock movement triggers.

By the numbersConsolidated · Q2 FY27 vs Q2 FY26

	Q2 FY27	Q2 FY26	Change
Revenue	₹4,338 Cr	₹3,697 Cr	+17.3%
Operating profit	₹830.6 Cr	₹529.8 Cr	+56.8%
Profit after tax	₹716.1 Cr	₹520.2 Cr	+37.7%
EBITDA margin	27.0%	24.9%	+2.1 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.